192 related articles for article (PubMed ID: 2671623)
1. Carboplatin.
Med Lett Drugs Ther; 1989 Sep; 31(800):83-4. PubMed ID: 2671623
[No Abstract] [Full Text] [Related]
2. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.
Evans BD; Raju KS; Calvert AH; Harland SJ; Wiltshaw E
Cancer Treat Rep; 1983 Nov; 67(11):997-1000. PubMed ID: 6315233
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin in refractory epithelial ovarian cancer.
Kavanagh JJ; Nicaise C
Semin Oncol; 1989 Apr; 16(2 Suppl 5):45-8. PubMed ID: 2655098
[No Abstract] [Full Text] [Related]
4. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
Abou-Jawde RM; Oberoi SS
J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
[No Abstract] [Full Text] [Related]
5. Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma--a word of caution.
McGuire WP; Abeloff MD
J Natl Cancer Inst; 1989 Oct; 81(19):1438-9. PubMed ID: 2674458
[No Abstract] [Full Text] [Related]
6. Carboplatin: the experience in head and neck cancer.
Eisenberger M; Van Echo D; Aisner J
Semin Oncol; 1989 Apr; 16(2 Suppl 5):34-41. PubMed ID: 2655096
[No Abstract] [Full Text] [Related]
7. [Antitumor activity of platinum analogs against human ovarian tumors heterotransplanted into nude mice].
Sawada M; Ozaki M; Hongo J; Hirota Y; Inagaki M; Taniguchi H; Tateishi R; Mori Y
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):693-8. PubMed ID: 3548596
[TBL] [Abstract][Full Text] [Related]
8. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
9. [Phase III study of carboplatin in ovarian cancer].
Kato T; Nishimura H; Yamabe T; Terashima Y; Kasamatsu T; Hirabayashi K; Nishiya I; Yajima A; Takamizawa H; Tsutsui F
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2297-304. PubMed ID: 3044276
[TBL] [Abstract][Full Text] [Related]
10. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Eisenhauer EA; Swenerton KD; Sturgeon JF; Fine S; O'Reilly SE
Cancer Treat Rep; 1986 Oct; 70(10):1195-8. PubMed ID: 3530446
[TBL] [Abstract][Full Text] [Related]
12. "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?
Markman M
Gynecol Oncol; 1998 May; 69(2):91-2. PubMed ID: 9600812
[No Abstract] [Full Text] [Related]
13. Whither carboplatin? A replacement for or an alternative to cisplatin?
Gil A
J Clin Oncol; 1987 Dec; 5(12):2041-2. PubMed ID: 3316520
[No Abstract] [Full Text] [Related]
14. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334
[TBL] [Abstract][Full Text] [Related]
15. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
[TBL] [Abstract][Full Text] [Related]
16. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the cochleovestibular function in patients treated with carboplatin for ovarian carcinoma.
Ragni N; Foglia G; Ruvolo M; Repetto P; Cordone G; Madaro M; Chiara S; Bruzzone M
Chemioterapia; 1986 Dec; 5(6):411-3. PubMed ID: 3542253
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
[TBL] [Abstract][Full Text] [Related]
19. Whither carboplatin.
J Clin Oncol; 1987 Jun; 5(6):984-6. PubMed ID: 3295133
[No Abstract] [Full Text] [Related]
20. Clinical status of carboplatin.
Canetta R; Franks C; Smaldone L; Bragman K; Rozencweig M
Oncology (Williston Park); 1987 Jul; 1(5):61-70. PubMed ID: 3079484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
